GS
ZVRA icon

GTS Securities’s Zevra Therapeutics ZVRA Stock Holding History

GTS Securities’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-24,100
Closed -$158K – 4523
2023
Q4 		$158K Sell
24,100
-9,800
-29% -$45.8K ﹤0.01% 3644
2023
Q3 		$163K Buy
+33,900
New +$169K ﹤0.01% 3476

Other funds holding ZVRA

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACM
Altium Capital Management New York $47.5M AUM 115.72% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

GTS Securities's ZVRA Position: Q4 2024 in Review

GTS Securities sold out of Zevra Therapeutics (ZVRA) in Q4 2024, closing a stake of 24,103 shares — an estimated $167K sold.

GTS Securities first reported a position in ZVRA in Q1 2024 and held it in 3 quarters. The position peaked at $167K in Q3 2024. 109 funds tracked by Wall St. Rank hold ZVRA as of Q4 2024.

  • GTS Securities reported no remaining Zevra Therapeutics position as of Q4 2024 after selling out during the quarter.
  • GTS Securities sold 24,103 Zevra Therapeutics shares in Q4 2024, an estimated $167K.
  • GTS Securities first reported a position in Zevra Therapeutics in Q1 2024 and held it in 3 quarters.
  • GTS Securities's Zevra Therapeutics position peaked at $167K in Q3 2024.
  • 109 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q4 2024.

Based on GTS Securities's 13F filing for Q4 2024, filed 18 Feb 2025.